Contract With Customer, Maximum Accepted Product

No definition available.

Name:	rxrx_ContractWithCustomerMaximumAcceptedProduct
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Performance Obligation, Number Of Obligations

+ References

No definition available.

+ Details

Name:	rxrx_RevenuePerformanceObligationNumberOfObligations
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated

+ References

No definition available.

+ Details

Name:	rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	rxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsCreationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsRawImagesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_DevelopedAndCommercializedProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_GastrointestinalCancerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_NeuroscienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Development Contracts (Details) $ in Thousands	1 Months Ended
	Jan. 31, 2022 USD ($) program performance_obligation phenomap	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unearned revenue		$ 36,618	$ 36,426
Collaborative arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unearned revenue		$ 6,500
Roche and Genentech \| Collaborative arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining unearned revenue	$ 150,000
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation	3
Remaining performance obligation revenue	$ 150,000
Roche and Genentech \| Collaborative arrangement \| Phenomaps creation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research project, fees and milestones payments receivable for an option on a lead series	$ 250,000
Number of eligible phenomaps (in phenomaps) \| phenomap	16
Roche and Genentech \| Collaborative arrangement \| Phenomaps raw images
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research project, fees and milestones payments receivable for an option on a lead series	$ 250,000
Number of eligible phenomaps (in phenomaps) \| phenomap	12
Roche and Genentech \| Collaborative arrangement \| Developed and commercialized programs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research project, fees and milestones payments receivable for an option on a lead series	$ 300,000
Number of projects that may be initiated (in projects) \| program	40
Roche and Genentech \| Collaborative arrangement \| Gastrointestinal cancer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation	1
Roche and Genentech \| Collaborative arrangement \| Neuroscience
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation	2